EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real-World Safety and Tolerability of Rapid, 30-Minutes, Intravenous Isatuximab in Patients With Multiple Myeloma

Rami Kotb, Marc Geirnaert, Emily Rimmer, Vi Dao, Jayne Kasian, Leonard Minuk, Ivan Landego

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.01.022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Rami Kotb und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Care Manitoba, Winnipeg, MB, Canada. Electronic address: rkotb@cancercare.mb.ca. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Isatuximab-based combinations are widely used to treat patients with relapsed or refractory multiple myeloma, and will soon become part of the standard first-line therapies in transplant-eligible and transplant-ineligible newly diagnosed patients. Isatuximab is currently approved for intravenous fixed volume (250ml) administration, with a maximum infusion rate of 200 ml/h and at least 75 minutes required for 1 administration. A recent clinical trial suggested the safety of a faster, 30-minute administration of isatuximab. Other trials are ongoing. Based on this early data as well as previous experience with monoclonal antibody therapies, the rapid, 30-minutes intravenous isatuximab administration was adopted at our institution as standard of care. METHODOLOGY: We here report the early real-world data on this new standard.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntibodies, Monoclonal, HumanizedHumansMaleFemaleAgedMiddle AgedInfusions, IntravenousAdministration, Intravenous

Stichwörter der Autor:innen

IsatuximabMultiple myelomaRapid 30-minutes administrationReal-worldSafety and tolerability

Substanzen

Antibodies, Monoclonal, Humanizedisatuximab

Autor:innen und Institutionen

  • Cancer Care Manitoba, Winnipeg, MB, Canada. Electronic address: rkotb@cancercare.mb.ca.
  • Cancer Care Manitoba, Winnipeg, MB, Canada.

Zitieren

APA

Kotb, R., Geirnaert, M., Rimmer, E., Dao, V., Kasian, J., Minuk, L., & Landego, I. (2025). Real-World Safety and Tolerability of Rapid, 30-Minutes, Intravenous Isatuximab in Patients With Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.01.022

Vancouver

Kotb R, Geirnaert M, Rimmer E, Dao V, Kasian J, Minuk L, et al. Real-World Safety and Tolerability of Rapid, 30-Minutes, Intravenous Isatuximab in Patients With Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.01.022

BibTeX
@article{Kotb2025,
  author = {Kotb, Rami and Geirnaert, Marc and Rimmer, Emily and Dao, Vi and Kasian, Jayne and Minuk, Leonard and Landego, Ivan},
  title = {Real-World Safety and Tolerability of Rapid, 30-Minutes, Intravenous Isatuximab in Patients With Multiple Myeloma},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.01.022}
}
Kostenlos starten →